Estrogen replacement therapy and risk of lung cancer
Purpose Some epidemiological data suggest that sex hormones may influence lung cancer risk, and estrogen receptors have been found in human non‐small cell lung tumors. We assessed the relation of the use of estrogen replacement therapy (ERT) to the risk of lung cancer in our hospital‐based Case–Cont...
Gespeichert in:
| Veröffentlicht in: | Pharmacoepidemiology and drug safety 2002-10, Vol.11 (7), p.561-567 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 567 |
|---|---|
| container_issue | 7 |
| container_start_page | 561 |
| container_title | Pharmacoepidemiology and drug safety |
| container_volume | 11 |
| creator | Blackman, Janine A. Coogan, Patricia F. Rosenberg, Lynn Strom, Brian L. Zauber, Ann G. Palmer, Julie R. Langenberg, Patricia Shapiro, Samuel |
| description | Purpose
Some epidemiological data suggest that sex hormones may influence lung cancer risk, and estrogen receptors have been found in human non‐small cell lung tumors. We assessed the relation of the use of estrogen replacement therapy (ERT) to the risk of lung cancer in our hospital‐based Case–Control Surveillance Study, conducted in four US centers during 1976 to 2001.
Methods
Cases were 662 women aged 40 through 74 years with lung cancer and controls were 4671 women admitted for conditions unrelated to ERT use. We used multivariate unconditional logistic regression models to estimate odds ratios (OR) and 95% confidence intervals (CI) for ERT use for at least 3 months compared to no use or use for less than 3 months.
Results
The OR for lung cancer among ERT users was 1.0 (95%CI 0.8–1.4), and it was 1.0 (95%CI 0.7–1.4) among users of conjugated estrogens only. Risk did not increase as the duration of use increased. Odds ratios for specific lung cancer cell types were not significantly increased or decreased for use of ERT or conjugated estrogens. There were non‐significant increases for non‐small cell types other than squamous, but there was no consistent pattern across duration of use.
Conclusion
Our data do not support an increased risk of lung cancer among women who use ERT. Copyright © 2002 John Wiley & Sons, Ltd. |
| doi_str_mv | 10.1002/pds.733 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_pds_733</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PDS733</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3513-d0eb3f458b9ec0e2b77a4610c6985f588bc0a62acfd651363fb56b5ccad2dac93</originalsourceid><addsrcrecordid>eNp1z01LwzAcx_EgiptTfAeSmwfpzEOTNkeZcxPGVFQmXkKeOuu6tiQdundvR4eePOUP-fCDLwDnGA0xQuS6tmGYUHoA-hgJEWHGksPdzWiUMi564CSET4TaPxEfgx4mMSeYkj6Ix6Hx1dKV0Lu6UMatXdnA5sN5VW-hKi30eVjBKoPFplxCo0rj_Ck4ylQR3Nn-HYDXu_HLaBrNHib3o5tZZCjDNLLIaZrFLNXCGeSIThIVc4wMFynLWJpqgxQnymSWt57TTDOumTHKEquMoANw2e0aX4XgXSZrn6-V30qM5K5btt2y7W7lRSfrjV47--f2oS246sBXXrjtfzvy8fa5m4s6nYfGff9q5VeSJzRhcjGfyAWdv8XTp3c5oj-HvnBC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Estrogen replacement therapy and risk of lung cancer</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Blackman, Janine A. ; Coogan, Patricia F. ; Rosenberg, Lynn ; Strom, Brian L. ; Zauber, Ann G. ; Palmer, Julie R. ; Langenberg, Patricia ; Shapiro, Samuel</creator><creatorcontrib>Blackman, Janine A. ; Coogan, Patricia F. ; Rosenberg, Lynn ; Strom, Brian L. ; Zauber, Ann G. ; Palmer, Julie R. ; Langenberg, Patricia ; Shapiro, Samuel</creatorcontrib><description>Purpose
Some epidemiological data suggest that sex hormones may influence lung cancer risk, and estrogen receptors have been found in human non‐small cell lung tumors. We assessed the relation of the use of estrogen replacement therapy (ERT) to the risk of lung cancer in our hospital‐based Case–Control Surveillance Study, conducted in four US centers during 1976 to 2001.
Methods
Cases were 662 women aged 40 through 74 years with lung cancer and controls were 4671 women admitted for conditions unrelated to ERT use. We used multivariate unconditional logistic regression models to estimate odds ratios (OR) and 95% confidence intervals (CI) for ERT use for at least 3 months compared to no use or use for less than 3 months.
Results
The OR for lung cancer among ERT users was 1.0 (95%CI 0.8–1.4), and it was 1.0 (95%CI 0.7–1.4) among users of conjugated estrogens only. Risk did not increase as the duration of use increased. Odds ratios for specific lung cancer cell types were not significantly increased or decreased for use of ERT or conjugated estrogens. There were non‐significant increases for non‐small cell types other than squamous, but there was no consistent pattern across duration of use.
Conclusion
Our data do not support an increased risk of lung cancer among women who use ERT. Copyright © 2002 John Wiley & Sons, Ltd.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.733</identifier><identifier>PMID: 12462132</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Adult ; Aged ; Case-Control Studies ; estrogen replacement therapy ; Estrogen Replacement Therapy - adverse effects ; Female ; Humans ; Logistic Models ; lung cancer ; Lung Neoplasms - chemically induced ; Lung Neoplasms - epidemiology ; Middle Aged ; Odds Ratio ; pharmacoepidemiology ; Risk Factors ; Smoking ; Surveys and Questionnaires ; United States - epidemiology</subject><ispartof>Pharmacoepidemiology and drug safety, 2002-10, Vol.11 (7), p.561-567</ispartof><rights>Copyright © 2002 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3513-d0eb3f458b9ec0e2b77a4610c6985f588bc0a62acfd651363fb56b5ccad2dac93</citedby><cites>FETCH-LOGICAL-c3513-d0eb3f458b9ec0e2b77a4610c6985f588bc0a62acfd651363fb56b5ccad2dac93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpds.733$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpds.733$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27911,27912,45561,45562</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12462132$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Blackman, Janine A.</creatorcontrib><creatorcontrib>Coogan, Patricia F.</creatorcontrib><creatorcontrib>Rosenberg, Lynn</creatorcontrib><creatorcontrib>Strom, Brian L.</creatorcontrib><creatorcontrib>Zauber, Ann G.</creatorcontrib><creatorcontrib>Palmer, Julie R.</creatorcontrib><creatorcontrib>Langenberg, Patricia</creatorcontrib><creatorcontrib>Shapiro, Samuel</creatorcontrib><title>Estrogen replacement therapy and risk of lung cancer</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidem. Drug Safe</addtitle><description>Purpose
Some epidemiological data suggest that sex hormones may influence lung cancer risk, and estrogen receptors have been found in human non‐small cell lung tumors. We assessed the relation of the use of estrogen replacement therapy (ERT) to the risk of lung cancer in our hospital‐based Case–Control Surveillance Study, conducted in four US centers during 1976 to 2001.
Methods
Cases were 662 women aged 40 through 74 years with lung cancer and controls were 4671 women admitted for conditions unrelated to ERT use. We used multivariate unconditional logistic regression models to estimate odds ratios (OR) and 95% confidence intervals (CI) for ERT use for at least 3 months compared to no use or use for less than 3 months.
Results
The OR for lung cancer among ERT users was 1.0 (95%CI 0.8–1.4), and it was 1.0 (95%CI 0.7–1.4) among users of conjugated estrogens only. Risk did not increase as the duration of use increased. Odds ratios for specific lung cancer cell types were not significantly increased or decreased for use of ERT or conjugated estrogens. There were non‐significant increases for non‐small cell types other than squamous, but there was no consistent pattern across duration of use.
Conclusion
Our data do not support an increased risk of lung cancer among women who use ERT. Copyright © 2002 John Wiley & Sons, Ltd.</description><subject>Adult</subject><subject>Aged</subject><subject>Case-Control Studies</subject><subject>estrogen replacement therapy</subject><subject>Estrogen Replacement Therapy - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>lung cancer</subject><subject>Lung Neoplasms - chemically induced</subject><subject>Lung Neoplasms - epidemiology</subject><subject>Middle Aged</subject><subject>Odds Ratio</subject><subject>pharmacoepidemiology</subject><subject>Risk Factors</subject><subject>Smoking</subject><subject>Surveys and Questionnaires</subject><subject>United States - epidemiology</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1z01LwzAcx_EgiptTfAeSmwfpzEOTNkeZcxPGVFQmXkKeOuu6tiQdundvR4eePOUP-fCDLwDnGA0xQuS6tmGYUHoA-hgJEWHGksPdzWiUMi564CSET4TaPxEfgx4mMSeYkj6Ix6Hx1dKV0Lu6UMatXdnA5sN5VW-hKi30eVjBKoPFplxCo0rj_Ck4ylQR3Nn-HYDXu_HLaBrNHib3o5tZZCjDNLLIaZrFLNXCGeSIThIVc4wMFynLWJpqgxQnymSWt57TTDOumTHKEquMoANw2e0aX4XgXSZrn6-V30qM5K5btt2y7W7lRSfrjV47--f2oS246sBXXrjtfzvy8fa5m4s6nYfGff9q5VeSJzRhcjGfyAWdv8XTp3c5oj-HvnBC</recordid><startdate>20021001</startdate><enddate>20021001</enddate><creator>Blackman, Janine A.</creator><creator>Coogan, Patricia F.</creator><creator>Rosenberg, Lynn</creator><creator>Strom, Brian L.</creator><creator>Zauber, Ann G.</creator><creator>Palmer, Julie R.</creator><creator>Langenberg, Patricia</creator><creator>Shapiro, Samuel</creator><general>John Wiley & Sons, Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20021001</creationdate><title>Estrogen replacement therapy and risk of lung cancer</title><author>Blackman, Janine A. ; Coogan, Patricia F. ; Rosenberg, Lynn ; Strom, Brian L. ; Zauber, Ann G. ; Palmer, Julie R. ; Langenberg, Patricia ; Shapiro, Samuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3513-d0eb3f458b9ec0e2b77a4610c6985f588bc0a62acfd651363fb56b5ccad2dac93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Case-Control Studies</topic><topic>estrogen replacement therapy</topic><topic>Estrogen Replacement Therapy - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>lung cancer</topic><topic>Lung Neoplasms - chemically induced</topic><topic>Lung Neoplasms - epidemiology</topic><topic>Middle Aged</topic><topic>Odds Ratio</topic><topic>pharmacoepidemiology</topic><topic>Risk Factors</topic><topic>Smoking</topic><topic>Surveys and Questionnaires</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Blackman, Janine A.</creatorcontrib><creatorcontrib>Coogan, Patricia F.</creatorcontrib><creatorcontrib>Rosenberg, Lynn</creatorcontrib><creatorcontrib>Strom, Brian L.</creatorcontrib><creatorcontrib>Zauber, Ann G.</creatorcontrib><creatorcontrib>Palmer, Julie R.</creatorcontrib><creatorcontrib>Langenberg, Patricia</creatorcontrib><creatorcontrib>Shapiro, Samuel</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Blackman, Janine A.</au><au>Coogan, Patricia F.</au><au>Rosenberg, Lynn</au><au>Strom, Brian L.</au><au>Zauber, Ann G.</au><au>Palmer, Julie R.</au><au>Langenberg, Patricia</au><au>Shapiro, Samuel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Estrogen replacement therapy and risk of lung cancer</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidem. Drug Safe</addtitle><date>2002-10-01</date><risdate>2002</risdate><volume>11</volume><issue>7</issue><spage>561</spage><epage>567</epage><pages>561-567</pages><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>Purpose
Some epidemiological data suggest that sex hormones may influence lung cancer risk, and estrogen receptors have been found in human non‐small cell lung tumors. We assessed the relation of the use of estrogen replacement therapy (ERT) to the risk of lung cancer in our hospital‐based Case–Control Surveillance Study, conducted in four US centers during 1976 to 2001.
Methods
Cases were 662 women aged 40 through 74 years with lung cancer and controls were 4671 women admitted for conditions unrelated to ERT use. We used multivariate unconditional logistic regression models to estimate odds ratios (OR) and 95% confidence intervals (CI) for ERT use for at least 3 months compared to no use or use for less than 3 months.
Results
The OR for lung cancer among ERT users was 1.0 (95%CI 0.8–1.4), and it was 1.0 (95%CI 0.7–1.4) among users of conjugated estrogens only. Risk did not increase as the duration of use increased. Odds ratios for specific lung cancer cell types were not significantly increased or decreased for use of ERT or conjugated estrogens. There were non‐significant increases for non‐small cell types other than squamous, but there was no consistent pattern across duration of use.
Conclusion
Our data do not support an increased risk of lung cancer among women who use ERT. Copyright © 2002 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>12462132</pmid><doi>10.1002/pds.733</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1053-8569 |
| ispartof | Pharmacoepidemiology and drug safety, 2002-10, Vol.11 (7), p.561-567 |
| issn | 1053-8569 1099-1557 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_pds_733 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Case-Control Studies estrogen replacement therapy Estrogen Replacement Therapy - adverse effects Female Humans Logistic Models lung cancer Lung Neoplasms - chemically induced Lung Neoplasms - epidemiology Middle Aged Odds Ratio pharmacoepidemiology Risk Factors Smoking Surveys and Questionnaires United States - epidemiology |
| title | Estrogen replacement therapy and risk of lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T19%3A41%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Estrogen%20replacement%20therapy%20and%20risk%20of%20lung%20cancer&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Blackman,%20Janine%20A.&rft.date=2002-10-01&rft.volume=11&rft.issue=7&rft.spage=561&rft.epage=567&rft.pages=561-567&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.733&rft_dat=%3Cwiley_cross%3EPDS733%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12462132&rfr_iscdi=true |